stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Net income
Ionis Pharmaceuticals, Inc.'s net income for fiscal 2025 was −$381.4M, compared with −$453.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$565.2M. Over the past ten years it has ranged from −$479.7M (fiscal 2020) to $287.3M (fiscal 2019); the current reading is higher than 27% of that period. Ionis Pharmaceuticals, Inc. ranks 590th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$381.4M | — |
| FY2024 | −$453.9M | — |
| FY2023 | −$366.3M | — |
| FY2022 | −$269.7M | — |
| FY2021 | −$28.6M | — |
| FY2020 | −$479.7M | — |
| FY2019 | $287.3M | 33.62% |
| FY2018 | $215.0M | — |
| FY2017 | −$10.8M | — |
| FY2016 | −$60.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$114.6M | — |
| Mar 2026 | −$92.5M | — |
| Dec 2025 | −$229.4M | — |
| Sep 2025 | −$128.6M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $51.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$132.9M |
| AXSM Axsome Therapeutics, Inc. compare | −$157.3M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| IMVT Immunovant, Inc. compare | −$538.2M |
| IONS Ionis Pharmaceuticals, Inc. | −$565.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on IONS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement